Presymptom: development of a novel machine-learning-derived diagnostic test to rule out infection to enable enhanced clinical care and better targeted anti-microbial use

症状前：开发一种新型的机器学习诊断测试来排除感染，从而加强临床护理和更有针对性的抗菌药物使用

• 批准号: 10089281
• 金额: $ 62.02万
• 依托单位: PRESYMPTOM HEALTH LIMITED
• 依托单位国家: 英国
• 项目类别: Investment Accelerator
• 财政年份: 2024
• 资助国家: 英国
• 起止时间: 2024 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10089281
• 关键词: Presymptom; development; novel; machine; learning

Presymptom Health, a UK-based start-up, is pioneering a portfolio of novel, universal, low-cost diagnostic tests and associated interpretive software algorithms to rule out the presence of infection/sepsis in symptomatic patients.Presymptom has developed a prototype version of a simple blood test and associated prototype interpretive software to rule out infection from whole blood in post-operative inflamed SIRS (Systemic Inflammatory Response Syndrome) patients. Results can be used to delay or eliminate the use of antibiotics in such SIRS patients who present with symptoms suggestive of potential infection but who in reality have no infection, allowing such patients to be managed instead on a more appropriate care pathway. This will in turn reduce the spread of Antimicrobial Resistance (AMR) and lead to better patient outcomes.Presymptom's product will comprise a simple blood test to assess host gene expression and associated interpretive software to gauge risk of infection in SIRS patients. The test will run on ubiquitous clinical instrumentation, specifically platforms commonly used within clinical testing labs for routine quantitative RT-PCR based diagnostics, including the many new such instruments deployed since the COVID pandemic. Presymptom's technology platform was discovered based on application of machine learning to a unique fully-annotated presymptomatic database owned by the UK Defence Science & Technologies Laboratory (Dstl).Current diagnostic approaches to assess infection status include:* **Observations**: Temperature/Resp. rate/heart-rate/urine output/blood pressure/O2 saturation/appearance/rash. In general, these lack specificty and lead to overuse of antimicrobials.* **Blood markers**: also lack specificity, CRP, PCT, lactate, urea & electrolytes, glucose, creatine, blood gas, full blood count* **Microbiology&Culture**: blood culture (BC) sets (1-3 days to result, low sensitivity & high false positive), swabs from multiple sites, PCR from swabs if appropriate.The main objective of this project is to develop and validate a rapid novel diagnostic test to rule out the presence of infection in post-operative patients, thereby mitigating AMR, reducing hospital costs and delivering improved patient outcomes.

Presymptom Health, a UK-based start-up, is pioneering a portfolio of novel, universal, low-cost diagnostic tests and associated interpretive software algorithms to rule out the presence of infection/sepsis in symptomatic patients.Presymptom has developed a prototype version of a simple blood test and associated prototype interpretive software to rule out infection from whole blood in post-operative inflamed SIRS (Systemic Inflammatory Response Syndrome) patients.结果可用于在此类SIRS患者中延迟或消除抗生素的使用，这些患者表现出可能感染的症状，但实际上没有感染，可以在更合适的护理途径上进行治疗。反过来，这将减少抗菌素耐药性（AMR）的传播，并导致更好的患者结局。Presymptom的产品将包括一项简单的血液测试，以评估宿主基因表达和相关的解释性软件，以衡量SIRS患者感染的风险。该测试将在无处不在的临床仪器上进行，特别是在临床测试实验室中常用的平台，用于常规定量的基于RT-PCR的诊断，包括自相互作用以来部署的许多新此类仪器。根据将机器学习应用于英国国防科学与技术实验室（DSTL）拥有的独特的全已通量的预症状数据库（DSTL），发现了Presymptom的技术平台（DSTL）。速率/心率/尿量/血压/O2饱和/外观/皮疹。通常，这些缺乏特定的抗菌药物过度使用。该项目的主要目的是开发和验证快速的新型诊断测试，以排除术后患者中感染的存在，从而减轻AMR，降低医院成本并提供改善的患者结局。